1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010,60: 277-300.
2Bonekamp D, Macura KJ. Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate [ J ]. Top Magn Reson Imaging, 2008,19: 273-284.
3Nicholson B, Schaefer G, Theodorescu D, et al. Angiogenesis in prostate cancer: biology and therapeutic opportunities [J]. Cancer Metastasis Rev, 2001,20: 297-319.
4Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma[J ]. Am J Pathol, 1993,143: 401-409.
5Stefanou D, Batistatou A, Kamina S, et al. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer[J]. In Vivo, 2004,18: 155-160.
6Franiel T, Hamm B, Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer [J]. Eur Radiol, 2011,21: 616-626.
7Ren J, Huan Y, Wang H, et al. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma:correlation with angiogenesis[J]. Clin Radiol, 2008,63: 153-159.
8Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer[J ]. Eur J Radiol, 2007,63: 335-350.
9Oostendorp M, Post MJ, Backes WH. Vessel growth and function: depiction with contrast-enhanced MR imaging [J ]. Radiology, 2009, 251: 317-335.
10Brown G, Macvicar DA, Ayton V. The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma [J]. Clin Radiol, 1995,50: 601-606.
10Kuhl C,Weiqel S,Schrading S,et al.Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer:the EVA trial[J].J Clin Oncol,2010,28:1450-1457.
